Skip to main content Back to Top
Advertisement

10/25/2022

Acetaminophen Suppositories

Products Affected - Description

    • Acetaminophen rectal suppository, Padagis, 120 mg, 12 count, NDC 45802-0732-30
    • Acetaminophen rectal suppository, Padagis, 120 mg, 100 count, NDC 45802-0732-33
    • Acetaminophen rectal suppository, Padagis, 650 mg, 12 count, NDC 45802-0730-30
    • Acetaminophen rectal suppository, Padagis, 650 mg, 50 count, NDC 45802-0730-32
    • Acetaminophen rectal suppository, Padagis, 650 mg, 100 count, NDC 45802-0730-33

Reason for the Shortage

    • Padagis did not provide a reason for the shortage.
    • Taro has acetaminophen suppositories available.
    • Additional over-the-counter acetaminophen suppository products may be available from store brands. These companies do not provide availability information.

Available Products

    • Acetaminophen rectal suppository, Taro, 120 mg, 6 count, NDC 51672-2115-02
    • Acetaminophen rectal suppository, Taro, 325 mg, 6 count, NDC 51672-2116-02
    • Acetaminophen rectal suppository, Taro, 80 mg, 6 count, NDC 51672-2114-02

Estimated Resupply Dates

    • Padagis has acetaminophen 120 mg suppositories in 12 count and 100 count boxes on back order and the company estimates a release date of early-November 2022. The 650 mg suppositories in 12 count and 50 count boxes are on back order and the company estimates a release date of late-November 2022. The 650 mg suppositories in 100 count boxes are on back order and the company estimates a release date of mid-November 2022.

Updated

Updated October 25, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 1, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.